Suppr超能文献

无义介导的 RNA 衰减是携带 或 突变的癌细胞的独特弱点。

Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring or Mutations.

机构信息

Department of Cell Biology and Physiology, School of Medicine, Washington University in St. Louis, St. Louis, Missouri.

Division of Hematology and Oncology, Department of Medicine, School of Medicine, Washington University School in St. Louis, St. Louis, Missouri.

出版信息

Cancer Res. 2021 Sep 1;81(17):4499-4513. doi: 10.1158/0008-5472.CAN-20-4016. Epub 2021 Jul 2.

Abstract

Nonsense-mediated RNA decay (NMD) is recognized as an RNA surveillance pathway that targets aberrant mRNAs with premature translation termination codons (PTC) for degradation, however, its molecular mechanisms and roles in health and disease remain incompletely understood. In this study, we developed a novel reporter system to accurately measure NMD activity in individual cells. A genome-wide CRISPR-Cas9 knockout screen using this reporter system identified novel NMD-promoting factors, including multiple components of the SF3B complex and other U2 spliceosome factors. Interestingly, cells with mutations in the spliceosome genes and , which are commonly found in myelodysplastic syndrome (MDS) and cancers, have overall attenuated NMD activity. Compared with wild-type (WT) cells, SF3B1- and U2AF1-mutant cells were more sensitive to NMD inhibition, a phenotype that is accompanied by elevated DNA replication obstruction, DNA damage, and chromosomal instability. Remarkably, the sensitivity of spliceosome mutant cells to NMD inhibition was rescued by overexpression of RNase H1, which removes R-loops in the genome. Together, these findings shed new light on the functional interplay between NMD and RNA splicing and suggest a novel synthetic lethal strategy for the treatment of MDS and cancers with spliceosome mutations. SIGNIFICANCE: This study has developed a novel NMD reporter system and identified a potential therapeutic approach of targeting the NMD pathway to treat cancer with spliceosome gene mutations.

摘要

无意义介导的 RNA 衰减(NMD)被认为是一种 RNA 监测途径,可针对具有过早翻译终止密码子(PTC)的异常 mRNA 进行降解,然而,其分子机制及其在健康和疾病中的作用仍不完全清楚。在这项研究中,我们开发了一种新的报告系统,可以准确测量单个细胞中的 NMD 活性。使用该报告系统的全基因组 CRISPR-Cas9 敲除筛选鉴定了新的 NMD 促进因子,包括 SF3B 复合物的多个成分和其他 U2 剪接体因子。有趣的是,具有剪接体基因 和 突变的细胞(在骨髓增生异常综合征(MDS)和癌症中常见)的总体 NMD 活性减弱。与野生型(WT)细胞相比,SF3B1 和 U2AF1 突变细胞对 NMD 抑制更敏感,这种表型伴随着 DNA 复制受阻、DNA 损伤和染色体不稳定的增加。值得注意的是,通过表达 RNase H1 (可去除基因组中的 R-环)可挽救剪接体突变细胞对 NMD 抑制的敏感性。总之,这些发现揭示了 NMD 和 RNA 剪接之间的功能相互作用,并为治疗具有剪接体突变的 MDS 和癌症提供了一种新的合成致死策略。

意义

本研究开发了一种新的 NMD 报告系统,并确定了一种靶向 NMD 途径的潜在治疗方法,以治疗具有剪接体基因突变的癌症。

相似文献

1
Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring or Mutations.
Cancer Res. 2021 Sep 1;81(17):4499-4513. doi: 10.1158/0008-5472.CAN-20-4016. Epub 2021 Jul 2.
2
Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.
Trends Genet. 2017 May;33(5):336-348. doi: 10.1016/j.tig.2017.03.001. Epub 2017 Mar 31.
4
Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
Cancer Res. 2018 Sep 15;78(18):5363-5374. doi: 10.1158/0008-5472.CAN-17-3970. Epub 2018 Jul 27.
5
Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
Genes Dev. 2020 Mar 1;34(5-6):413-427. doi: 10.1101/gad.332270.119. Epub 2020 Jan 30.
6
Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1.
Mol Cell. 2019 Oct 3;76(1):82-95.e7. doi: 10.1016/j.molcel.2019.07.017. Epub 2019 Aug 29.
7
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
Blood. 2018 Sep 20;132(12):1225-1240. doi: 10.1182/blood-2018-04-843771. Epub 2018 Jun 21.
9
Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
Oncotarget. 2016 Mar 1;7(9):9951-63. doi: 10.18632/oncotarget.7127.
10
SF3B1 mutant myelodysplastic syndrome: Recent advances.
Adv Biol Regul. 2021 Jan;79:100776. doi: 10.1016/j.jbior.2020.100776. Epub 2020 Dec 25.

引用本文的文献

3
Steering research on mRNA splicing in cancer towards clinical translation.
Nat Rev Cancer. 2024 Dec;24(12):887-905. doi: 10.1038/s41568-024-00750-2. Epub 2024 Oct 9.
5
Molecular impact of mutations in RNA splicing factors in cancer.
Mol Cell. 2024 Oct 3;84(19):3667-3680. doi: 10.1016/j.molcel.2024.07.019. Epub 2024 Aug 14.
6
Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis.
JHEP Rep. 2024 May 9;6(8):101118. doi: 10.1016/j.jhepr.2024.101118. eCollection 2024 Aug.

本文引用的文献

2
Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
Genes Dev. 2020 Mar 1;34(5-6):413-427. doi: 10.1101/gad.332270.119. Epub 2020 Jan 30.
3
The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy.
Nat Genet. 2019 Nov;51(11):1645-1651. doi: 10.1038/s41588-019-0517-5. Epub 2019 Oct 28.
4
R Loops: From Physiological to Pathological Roles.
Cell. 2019 Oct 17;179(3):604-618. doi: 10.1016/j.cell.2019.08.055. Epub 2019 Oct 10.
5
A null allele of Dnaaf2 displays embryonic lethality and mimics human ciliary dyskinesia.
Hum Mol Genet. 2019 Aug 15;28(16):2775-2784. doi: 10.1093/hmg/ddz106.
6
Ca-Stimulated AMPK-Dependent Phosphorylation of Exo1 Protects Stressed Replication Forks from Aberrant Resection.
Mol Cell. 2019 Jun 20;74(6):1123-1137.e6. doi: 10.1016/j.molcel.2019.04.003. Epub 2019 Apr 30.
7
R-Loops as Cellular Regulators and Genomic Threats.
Mol Cell. 2019 Feb 7;73(3):398-411. doi: 10.1016/j.molcel.2019.01.024.
8
Human RNF113A participates of pre-mRNA splicing in vitro.
J Cell Biochem. 2019 May;120(5):8764-8774. doi: 10.1002/jcb.28163. Epub 2018 Dec 2.
9
Compound C inhibits nonsense-mediated RNA decay independently of AMPK.
PLoS One. 2018 Oct 5;13(10):e0204978. doi: 10.1371/journal.pone.0204978. eCollection 2018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验